Last Updated: April 13, 2026
Can Ketamine Treat Migraines? Benefits and Research
Ketamine is an FDA-approved anesthetic with decades of medical use that licensed providers now prescribe off-label for refractory chronic migraine, mood disorders, and other conditions. This article covers how ketamine works on migraine pain signals, when specialists consider it, how it is administered, and what the safety profile looks like.
Key takeaways
- In medical trials for refractory chronic migraine, approximately 50 to 75 percent of patients report clinically significant pain reduction following ketamine infusion therapy.
- Ketamine modulates glutamate and NMDA receptor activity in the brain, which may reduce the neural overactivity and central sensitization that drive chronic migraine pain.
- Specialists typically consider ketamine for refractory chronic migraine after multiple standard preventive and acute therapies have not provided adequate relief.
- Inpatient continuous ketamine infusion is reserved for the most severe cases, such as status migrainosus, while outpatient infusion series and non-infusion routes serve different severity levels and comorbidity profiles.
- Chronic migraine frequently co-occurs with depression, anxiety, and PTSD; for patients with these comorbidities, structured at-home ketamine therapy — such as Mindbloom's sublingual and subcutaneous program — addresses the mood condition alongside migraine-specific infusion protocols for the headache disorder.
Ketamine and Migraine Pain Signals in the Brain
Since 1970, ketamine has held FDA approval as an anesthetic, and the World Health Organization has listed it as an Essential Medicine since 1985. Today, licensed prescribers administer sub-anesthetic doses off-label across multiple care contexts, including chronic pain and migraine management.
Glutamate acts as the brain's primary excitatory neurotransmitter. In chronic migraine, glutamate signaling through NMDA receptors becomes dysregulated, contributing to central sensitization.
By modulating NMDA receptor activity, ketamine may interrupt the cycle of neural overactivity. Several distinct pathways explain how ketamine addresses headache disorders.
While preclinical and clinical evidence supports these mechanisms, research on ketamine specifically for migraine remains less extensive than for mood conditions. Understanding how ketamine interacts with the trigeminovascular system helps explain why it is biologically relevant to migraine pain signaling.1
When Specialists Consider Ketamine for Refractory Chronic Migraine
Physicians typically consider ketamine for individuals with chronic migraine who experience 15 or more headache days per month and have not responded adequately to standard treatments. The headache specialty community often refers to the condition as refractory migraine or intractable headache.
Ketamine serves as a short-term or rescue therapy for severe, refractory cases rather than a first-line preventive therapy, meaning patients have usually tried and not responded to several categories of prior care.
Response to ketamine varies, with reported improvement rates in refractory migraine trials generally ranging from 50 to 75 percent of patients.2 Relief typically lasts for weeks to months following the infusion protocol.
Candidacy is determined through comprehensive evaluation, not self-selection. A provider assesses the full treatment history, headache burden, and potential medication overuse headache before recommending ketamine for migraines.
Is Ketamine FDA Approved for Migraines?
As noted above, ketamine has held FDA approval as an anesthetic since 1970. It is not FDA-approved for migraine, meaning all use for headache disorders is off-label prescribing by licensed physicians.
Off-label prescribing is a widespread, legally accepted medical practice where a physician prescribes an approved medication for an unapproved indication based on medical judgment. Research indicates that approximately 21 percent of outpatient prescriptions are off-label.3 Physicians prescribe compounded ketamine and other formulations based on professional judgment and available evidence.6
The absence of an FDA indication for migraine does not mean ketamine lacks medical evidence for the use. It means ketamine has not received FDA approval for migraine, which can reflect both sponsor priorities and the absence of submitted evidence reviewed for that specific indication.
How Ketamine for Migraine Is Given and What to Expect
IV infusion is the most common administration route when ketamine is used for migraine. The specific protocol depends on the severity of the headache condition and the care context.
Preparation typically includes fasting guidelines, medication review, and arranging transportation. Dosing is sub-anesthetic and determined by the prescribing physician based on the patient's headache severity.
Inpatient Ketamine Infusion Protocols for Intractable Migraine
Inpatient protocols are typically used for the most severe cases, such as intractable migraine or status migrainosus. Ketamine is administered as a continuous infusion over multiple days in a hospital admission setting with ongoing vital signs monitoring.
Dosing is managed through careful titration by the care team based on patient response and tolerability. The intensive level of care is reserved for patients whose migraine has not broken with outpatient interventions.4
Outpatient Ketamine Infusion Protocols for Refractory Headache
Outpatient protocols involve shorter infusion sessions, typically lasting 40 minutes to a few hours, administered in an outpatient clinic. Patients complete an observation period before being released with a ride home.
Infusions may be given as a series over days or weeks, with dose titration managed by the treating specialist.
Non-Infusion Ketamine Routes and the Migraine Context
Non-infusion ketamine routes, including sublingual tablets, subcutaneous injection, intranasal, and intramuscular administration, are used in several medical contexts. The most relevant context for a reader managing chronic migraine is mood disorders, as chronic migraine frequently co-occurs with depression, anxiety, and PTSD.
Non-infusion at-home ketamine therapy is an established option for the mood conditions. The routes differ primarily by bioavailability and medical use.
For a patient whose headache condition co-occurs with depression, anxiety, or PTSD, non-infusion ketamine therapy is a legitimate therapeutic pathway for the mood comorbidity. It is not a substitute for migraine-specific care, as infusion-based ketamine remains the route studied for refractory migraine itself.
The Role of Clinical Protocols and Monitoring in Ketamine Therapy
Care protocols refer to the system of screening, monitoring, and follow-up that surrounds ketamine administration, regardless of the setting.7
Several key protocol elements work together to reduce risk and support patient safety.
For readers whose chronic migraine co-occurs with depression or anxiety, Mindbloom offers guided at-home ketamine therapy for the mood condition. Mindbloom offers programs of 6, 12, or 18 sessions.
After you select a program, a licensed provider conducts a comprehensive medical evaluation to determine whether ketamine is medically appropriate for you and to personalize your care plan. Mindbloom's at-home ketamine therapy starts at $165 per guided session for new clients, with programs billed in monthly installments.
For example, the 6-session program is $215 per session, billed as $430 per month for three months. Returning clients pay as little as $129 per session.
Building on decades of medical research, Mindbloom has published two of the largest peer-reviewed outcomes studies of at-home ketamine therapy. In a study of 11,441 patients, 89 percent of participants reported improvement in their depression and anxiety symptoms.5
Mindbloom is also the only at-home ketamine provider offering subcutaneous administration in addition to sublingual tablets. The comprehensive care model includes clinician consults, guide coaching, and unlimited Group Integration Circles.
Side Effects and Safety Considerations for Ketamine Therapy
It is important to distinguish between side effects, which are expected and non-serious reactions, and adverse events, which are serious and unexpected medical issues. In Mindbloom's published data, side effects occur in approximately 4 to 5 percent of sessions, while serious adverse events occur in fewer than 0.1 percent of sessions.5
Some people experience side effects during or after a ketamine session. The most frequently reported acute effects include nausea, dizziness, transient blood pressure elevation, headache, and sedation, all of which the care team anticipates and monitors throughout treatment.
Most people find the dissociative state therapeutically meaningful within a supervised setting. It is one of the mechanisms through which ketamine is thought to produce therapeutic benefit for mood conditions.
Abuse and dependence risk in supervised, sub-anesthetic therapeutic protocols is low. Ketamine is classified as a Schedule III controlled substance by the DEA.
Physician-supervised programs with defined treatment courses and screening for substance use disorders mitigate the risk. Urinary symptoms are rare but can occur with chronic, heavy recreational use, which differs significantly from therapeutic protocols.8
Ketamine therapy may not be appropriate for individuals with uncontrolled hypertension, psychotic disorders, or substance use disorders. As described in the screening protocol above, cardiovascular and psychiatric factors are evaluated before treatment begins. Individual results may vary.
Important Safety Information
Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information
Off-Label Use Disclosure
Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.
Frequently asked questions
How quickly does ketamine work for migraines?
In trials of refractory migraine, 50 to 75 percent of patients report noticeable pain reduction within hours to days after beginning a ketamine infusion protocol. The exact timeline depends on the severity of the migraine and the specific dosing schedule determined by the treating specialist.
Can ketamine cure chronic migraines permanently?
Ketamine is typically used as a rescue therapy to interrupt a severe migraine cycle, and relief may last for weeks or months.
Is ketamine therapy covered by insurance for migraines?
Because ketamine is prescribed off-label for migraines, insurance coverage varies widely and many plans do not cover the infusions. Patients can sometimes request a superbill to submit for potential partial reimbursement.
What does a ketamine for migraines feel like?
Patients often experience a sense of deep relaxation, or floating. The sensory changes are expected and are monitored closely by the care team.
Can I take my regular migraine medications with ketamine?
Your prescriber will conduct a thorough medication review during the screening process to identify any potential interactions. Some medications may need to be paused, while others can be safely continued.
How long does the post-session period last after a ketamine session?
The immediate post-session transition back to baseline usually takes a few hours. Patients are required to avoid driving or operating heavy machinery until after a full night of sleep.
Are there age restrictions for receiving ketamine for migraines?
Providers generally prescribe ketamine therapy for adults over the age of 18. Eligibility is determined by a licensed physician based on a comprehensive medical and psychiatric evaluation.
Mindbloom Treatment
See what might be possible with clinician-guided, at-home ketamine therapy. New client programs start at $165 per session.
Authors
